188 related articles for article (PubMed ID: 17613555)
1. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
Conti F; Ceccarelli F; Marocchi E; Magrini L; Spinelli FR; Spadaro A; Scrivo R; Valesini G
Ann Rheum Dis; 2007 Oct; 66(10):1393-7. PubMed ID: 17613555
[TBL] [Abstract][Full Text] [Related]
2. The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project.
Leeb BF; Böttcher E; Brezinschek HP; Czerwenka C; Herold M; Hitzelhammer H; Mayrhofer F; Puchner R; Rainer F; Rintelen B; Schirmer M; Stuby U; Bröll H
Clin Rheumatol; 2010 Feb; 29(2):167-74. PubMed ID: 19904485
[TBL] [Abstract][Full Text] [Related]
3. Long term safety of etanercept in elderly subjects with rheumatic diseases.
Fleischmann R; Baumgartner SW; Weisman MH; Liu T; White B; Peloso P
Ann Rheum Dis; 2006 Mar; 65(3):379-84. PubMed ID: 16150792
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of switching between biologics in psoriatic arthritis- results of a large regional survey.
Jani M; Macphie E; Rao C; Moore S; Mirjafari H; McLoughlin Y; Chinoy H; Shah P
Clin Med (Lond); 2014 Feb; 14(1):95-6. PubMed ID: 24532765
[No Abstract] [Full Text] [Related]
5. The effect of anti-TNF on renal function in patients with ankylosing spondylitis: a prospective cohort study.
Swart IAP; Visman IM; Heslinga M; van der Horst-Bruinsma IE; van Denderen JC; Nurmohamed MT
Clin Rheumatol; 2022 Dec; 41(12):3747-3752. PubMed ID: 35962246
[TBL] [Abstract][Full Text] [Related]
6. Compliance with NICE guidance on the use of anti-TNFalpha agents in ankylosing spondylitis: an east and west Midlands regional audit.
Rees F; Peffers G; Bell C; Obrenovic K; Sandhu R; Packham J; Erb N;
Clin Med (Lond); 2012 Aug; 12(4):324-7. PubMed ID: 22930875
[TBL] [Abstract][Full Text] [Related]
7. Infertility improved by etanercept in ankylosing spondylitis.
Rezvani A; Ozaras N
Indian J Pharmacol; 2008 Nov; 40(6):276-7. PubMed ID: 21279185
[TBL] [Abstract][Full Text] [Related]
8. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kalstad S; Rødevand E; Mikkelsen K; Lexberg AS; Kvien TK
Ann Rheum Dis; 2013 Nov; 72(11):1840-4. PubMed ID: 23562987
[TBL] [Abstract][Full Text] [Related]
9. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting.
Bonafede M; Johnson BH; Fox KM; Watson C; Gandra SR
J Dermatolog Treat; 2013 Oct; 24(5):369-73. PubMed ID: 23441722
[TBL] [Abstract][Full Text] [Related]
11. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
12. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N
Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232
[TBL] [Abstract][Full Text] [Related]
13. Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice.
Fabbroni M; Cantarini L; Caso F; Costa L; Pagano VA; Frediani B; Manganelli S; Galeazzi M
Mediators Inflamm; 2014; 2014():862969. PubMed ID: 25110401
[TBL] [Abstract][Full Text] [Related]
14. Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.
Glintborg B; Gudbjornsson B; Krogh NS; Omerovic E; Manilo N; Holland-Fischer M; Lindegaard HM; Loft AG; Nordin H; Johnsen L; Oeftiger SF; Hansen A; Rasmussen C; Grondal G; Geirsson AJ; Hetland ML
Rheumatology (Oxford); 2014 Nov; 53(11):2100-9. PubMed ID: 24939677
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample.
Yeaw J; Watson C; Fox KM; Schabert VF; Goodman S; Gandra SR
Adv Ther; 2014 Apr; 31(4):410-25. PubMed ID: 24604700
[TBL] [Abstract][Full Text] [Related]
16. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis.
Cawson MR; Mitchell SA; Knight C; Wildey H; Spurden D; Bird A; Orme ME
BMC Musculoskelet Disord; 2014 Jan; 15():26. PubMed ID: 24444034
[TBL] [Abstract][Full Text] [Related]
17. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
[TBL] [Abstract][Full Text] [Related]
18. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry.
Glintborg B; Østergaard M; Dreyer L; Krogh NS; Tarp U; Hansen MS; Rifbjerg-Madsen S; Lorenzen T; Hetland ML
Arthritis Rheum; 2011 Feb; 63(2):382-90. PubMed ID: 21279995
[TBL] [Abstract][Full Text] [Related]
19. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
20. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.
Haberhauer G; Strehblow C; Fasching P
Wien Med Wochenschr; 2010 May; 160(9-10):220-4. PubMed ID: 20632149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]